检索结果-南通市图书馆

Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2021年第1期8卷 132-137页

作者： Li-Bo Zhang Rong-Rong Pang Qing-Hua Qiao Zhi-Hua Wang Xin-Yi Xia Chang-Jun Wang Xiao-Li Xu COVID-19 Research Center Institute of Laboratory MedicineJinling HospitalNanjing University School of Medicinethe First School of Clinical MedicineSouthern Medical UniversityNanjing 210002JiangsuChina Department of Laboratory Medicine Nanjing Red Cross Blood CenterNanjing 210003JiangsuChina Medical and Technical Support Department Pingdingshan Medical Districtthe 989th HospitalPingdingshan 467000HenanChina Department of Laboratory Medicine&Blood Transfusion Wuhan Huoshenshan HospitalWuhan 430100HubeiChina Department of Laboratory Medicine&Blood Transfusion the 907th HospitalNanping 350702FujianChina Joint Expert Group for COVID-19 Wuhan Huoshenshan HospitalWuhan 430100HubeiChina Center for Disease Control and Prevention of PLA No.20 Dongda StreetFengtai DistrictBeijing 100071China Department of Medical Administration Jinling HospitalNanjing University School of MedicineNo.305 East Zhongshan RoadNanjing 210002JiangsuChina

Background: Gastrointestinal symptoms are not rare among coronavirus disease 2019(COVID-19) patients, but there have been no reports regarding convalescent plasma therapy for the recovery of gastrointestinal problems in COVID-19 *** presentation: We present two cases of patients with COVID-19-associated recurrent diarrhea and positive fecal occult blood who successfully recovered after a one-time convalescent plasma ***: When COVID-19 patients develop recurrent or refractory gastrointestinal symptoms and fail to respond to the available treatment, alternative therapy with convalescent plasma administration may be considered.

关键词： Coronavirus disease 2019(COVID-19) convalescent plasma SARS-Co V-2 virus Gastrointestinal symptoms

convalescent plasma as a therapeutic agent for SARS-CoV, MERS-CoV and SARS-CoV-2: A scoping review

在线全文

学校读者我要写书评

暂无评论

Journal of Acute Disease 2021年第2期10卷 47-56页

作者： Abeba Haile Mariamenatu Emebet Mohammed Abdu Department of Biotechnology College of Natural and Computational SciencesDebre Berhan UniversityP.O.Box 445Debre BerhanEthiopia Department of Biology College of Natural and Computational SciencesDebre Berhan UniversityP.O.Box 445Debre BerhanEthiopia

Severe acute respiratory syndrome coronavirus(SARS-CoV),Middle East respiratory syndrome coronavirus(MERS-CoV),and SARS-CoV-2 are three kinds of coronaviruses that are exceptionally pathogenic to humans via zoonotic *** outbreaks of SARS-CoV and MERS-CoV,and SARS-CoV-2,to some extent,posed a severe threat to human health,daily activities as well as the economic status of many *** faced with these emerging viruses and no accessible vaccines and drugs,convalescent plasma(CP)is required as passive immunotherapy,since CP has the potential to neutralize and eliminate the virus from blood *** sources of CP are individuals who have recovered from the ***,CP is administered as emergency use and investigational *** studies have shown that CP is effective to treat infected individuals with viral pandemics such as influenza A,Ebola virus,SARS-CoV,and ***,following the deadly outbreak of SARS-CoV-2 in 2019,plenty of non-randomized clinical studies have been done on the effectiveness of CP for the treatment of Coronavirus Disease 2019(COVID-19),and most of these studies have indicated that CP therapy is promising and saved many critically-ill ***,CP is a helpful immune therapeutic agent for the immediate response of such pandemics because of its clinical efficacy,immediate availability,cost-effectiveness,ease of production,delivery,and *** review aims to summarize the effectiveness of CP in the treatment of these three coronaviruses,***-CoV,MERS-CoV,and SARS-CoV-2.

关键词： convalescent plasma Coronaviruses SARS-CoV MERS-CoV SARS-CoV-2 COVID-19

Effectiveness and Controversy of convalescent plasma Therapy for Coronavirus Disease 2019 Patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2022年第1期2卷 49-54页

作者： Zhanjun Shu Peipei Wu Qianqian Qian Li Zhou Dandan Du Mengxuan Ding Tao Peng Ke Fang Research Institute of TCM of Affiliated Fourth Hospital in Xinjiang Medical University UrumuqiXinjiang 830000China The Eighth Affiliated Hospital of The Xinjiang Medical University UrumuqiXinjiang 830000China Department of Nephrology China-Japan Friendship HospitalNo.2East Yinghuayuan StreetBeijing 100029China Xinjiang Medical University UrumuqiXinjiang 830000China

Since the coronavirus disease 2019(COVID-19)began to spread,it remains pandemic *** European Medicines Agency’s human medicines committee and Food and Drug Administration have only granted a conditional marketing authorization for remdesivir to treat *** is essential to apply other valuable *** plasma(CP),donated by persons who have recovered from COVID-19,is the cellular component of blood that contains specific ***,to determine the feasibility of CP for COVID-19,the effectiveness and controversy are discussed in depth *** is suggested that CP plays a certain role in the treatment of *** a treatment,it may have its own indications and contraindications,which need to be further ***,it is critical to establish a standard procedure for treatment from CP collection,preservation,transport,to transfusion,and conduct some large sample randomized controlled trials to confirm the transfusion dosage,appropriate time,frequency,and actively prevent adverse outcomes that may occur.

关键词： COVID-19 Controversy convalescent plasma Effectiveness Therapy

The Progress and Challenges of convalescent plasma Therapy for Coronavirus Disease 2019

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2021年第1期1卷 52-58页

作者： Ming Shi Chao Zhang Fu-Sheng Wang Department of Infectious Diseases Fifth Medical Center of Chinese PLA General HospitalNational Clinical Research Center for Infectious DiseasesBeijing 100039China

Middle East respiratory syndrome(MERS),severe acute respiratory syndrome(SARS),and SARS-CoV-2 infection(causing coronavirus disease 2019[COVID-19])are serious *** date,no effective post-exposure prophylaxis,prevention,or therapeutic agents are recommended as effective for these *** plasma(CP),donated by individuals with established humoral immunity to the virus after recovering from coronavirus infection,has been successfully applied to treat several infectious diseases,including SARS,MERS,and ***,there are obstacles and challenges to using CP that should be taken into *** this review,we summarize the evidence derived from clinical attempts to treat COVID-19 with CP,which represents a promising therapy for severe coronavirus ***,we outline the remaining challenges and general issues that should be considered when using CP treatment for therapeutic or prophylactic purposes.

关键词： Clinical trial convalescent plasma COVID-19

Potential benefits,mechanisms,and uncertainties of convalescent plasma therapy for COVID-19

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Blood Science 2020年第3期2卷 71-75页

作者： Weiqian Dai Haihui Gu Sha Hao State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjinChina Department of Transfusion Medicine Changhai HospitalThe Second Military Medical UniversityShanghaiChina

The outbreak of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in China led to a public health emergency of international concern,putting all health organizations on high alert in the beginning of *** virus disease 2019(COVID-19)is highly infectious and has resulted in thousands of deaths which exceeded that of the SARS coronavirus(SARS-CoV)outbreak back in 2002 and 2003 in ***,the number of diagnosed patients,patients who are suspected to have contracted the disease,and deaths are increasing ***,effective drugs and vaccines to combat SARS-CoV-2 are still *** plasma,a seemingly successful treatment for COVID-19 patients,proved to be of huge value in terms of saving severely ill *** review introduces the reported effects,potential mechanisms,and future uncertainties of convalescent plasma therapy in the treatment of COVID-19 patients,in the hopes that it will provide useful information for relevant physicians and researchers.

关键词： SARS-CoV-2 COVID-19 convalescent plasma mechanisms adverse effects

Research on Antibody Changes and Nucleic Acid Clearance in COVID-19 Patients Treated with convalescent plasma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research on Antibody Changes and Nucleic Acid Clearance in C...

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

第十四届全国免疫学学术大会

作者： Guo yue Lin li Duan ying qing Wenlong Guan Jun Xu Zhiqiang Lin Quan Wang Chi Zhang The Eighth Affiliated Hospital of Xinjiang Medical University

Purpose:To investigate changes in the production of IgM and IgG antibodies and the negative transformation of viral nucleic acids in COVID-19 patients after convalescent plasma therapy,also to provide a basis for the treatment of COVID-1 9 using specific ***:Patients with a positive SARS-CoV-2 nucleic acid test were infused with convalescent plasma,and the IgM and IgG Ct values of antibodies in the recipient and the ORF1 Ab and N conditions of nucleic acid genes in the recipient were detected and statistically ***:In general,the Ct value and concentration of IgM and IgG antibodies in the plasma infusion group were significantly higher and 1-3 times higher than those in the non-plasma infusion group,respectively,but these diffe rences were not significant(P> 0.05).However,the contents of antibodies in severe patients in the plasma transfusion group were significantly higher than those in the non-plasma transfusion group at discharge,statistically significant(Pconvalescent plasma significantly increases the antibody content in severe and critical inpatients,effectively enhances immune function,accelerates the clearance of virus and the nucleic acid negative conversion rate,and significantly promotes early improvement in COVID-19 patients.

关键词： COVID-19 SARS-CoV-2 convalescent plasma antibody nucleic acid

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Military Medical Research 2020年第2期7卷 209-227页

作者： Xin-Ni Xu Yew Kwang Ong De Yun Wang Department of Otolaryngology-Head and Neck Surgery National University Hospital SystemSingaporeSingapore Department of Otolaryngology Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore

The coronavirus disease(COVID-19)pandemic has led to a global struggle to cope with the sheer numbers of infected persons,many of whom require intensive care support or eventually succumb to the *** outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are *** date,there is no specific anti-COVID-19 ***,the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome,especially in the severe to critically *** many of these adjunctive drugs are being investigated in clinical trials,professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate *** review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.

关键词： COVID-19 Adjunctive treatment Chloroquine Lopinavir-ritonavir Remdesivir Corticosteroids Umifenovir convalescent plasma

Understanding neutralising antibodies against SARS-CoV-2 and theirimplications in clinical practice

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2022年第2期9卷 215-230页

作者： Natalie Yan-Lin Pang Alexander Shao-Rong Pang Vincent T.Chow De-Yun Wang Yong Loo Lin School of Medicine National University of SingaporeSingapore 119228Singapore Department of Microbiology and Immunology National University of SingaporeScience Drive 2Singapore 117545Singapore Infectious Diseases Translational Research Program Yong Loo Lin School of MedicineNational University of SingaporeSingapore 119228Singapore Department of Otolaryngology Yong Loo Lin School of MedicineNational University of Singapore1E Kent Ridge RoadSingapore 119228Singapore

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a newly identified member of the coronavirus family that has caused the coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting SARS-CoV-2has disrupted the lives and livelihoods of millions worldwide. As of 23 August 2021, a total of 211,373,303 COVID-19cases have been confirmed globally with a death toll of 4,424,341. A strong understanding of the infection pathway of SARS-CoV-2, and how our immune system responds to the virus is highly pertinent for guiding the development and improvement of effective treatments. In this review, we discuss the current understanding of neutralising antibodies(NAbs) and their implications in clinical practice. The aspects include the pathophysiology of the immune response,particularly humoral adaptive immunity and the roles of NAbs from B cells in infection clearance. We summarise the onset and persistence of IgA, IgM and IgG antibodies, and we explore their roles in neutralising SARS-CoV-2, their persistence in convalescent individuals, and in reinfection. Furthermore, we also review the applications of neutralising antibodies in the clinical setting—from predictors of disease severity to serological testing to vaccinations, and finally in therapeutics such as convalescent plasma infusion.

关键词： Severe acute respiratory syndrome coronavirus Coronavirus disease 2019 Neutralising antibodies Persistence Spike glycoprotein Receptor-binding domain B cells T cells convalescent plasma

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

在线全文

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2020年第12期63卷 1833-1849页

作者： Ligong Lu Hui Zhang Meixiao Zhan Jun Jiang Hua Yin Danielle JDauphars Shi-You Li Yong Li You-Wen He Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhai 519000China First Affiliated Hospital China Medical UniversityShenyang 110001China tricision Biotherapeutic Inc. Zhuhai 519041China Department of Immunology Duke University Medical University Medical CenterDurhamNC 27710USA

The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019(COVID-19) due to SARSCoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARSCoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

关键词： COVID-19 seroconversion neutralizing antibody spike protein SARS-CoV-2 convalescent plasma vaccine